| Identification | Back Directory | [Name]
3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)- | [CAS]
1314556-93-8 | [Synonyms]
ZYJ34c
ZYJ-34c
ZYJ 34c
3-Isoquinolinecarboxamide, 2-[(2S,3S)-2-[(3,3-dimethyl-1-oxobutyl)amino]-3-methyl-1-oxopentyl]-1,2,3,4-tetrahydro-7-[2-(hydroxyamino)-2-oxoethoxy]-N-(4-methoxyphenyl)-, (3S)- | [Molecular Formula]
C31H42N4O7 | [MDL Number]
MFCD28160866 | [MOL File]
1314556-93-8.mol | [Molecular Weight]
582.69 |
| Hazard Information | Back Directory | [Description]
ZYJ-34c is a histone deacetylase inhibitor (HDACi) with potent oral antitumor activities. | [Uses]
ZYJ-34c is an orally active and potent histone deacetylase inhibitor (HDACi) with IC50s of 0.056 μM and 0.146 μM for HDAC6 and HDAC8, respectively. ZYJ-34c causes G1 phase arrest in low concentration. ZYJ-34c has antiproliferative activities. ZYJ-34c exhibits antitumor potency in MDA-MB-231 and HCT116 xenograft models and possesses antimetastatic potential in a mouse hepatoma-22 (H22) pulmonary metastasis model[1]. | [IC 50]
HDAC6: 0.056 μM (IC50); HDAC8: 0.146 μM (IC50) | [References]
[1] Yingjie Zhang, et al. Discovery of a tetrahydroisoquinoline-based hydroxamic acid derivative (ZYJ-34c) as histone deacetylase inhibitor with potent oral antitumor activities. J Med Chem. 2011 Aug 11;54(15):5532-9. DOI:10.1021/jm200577a |
|
|